본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Endoscopy v.49 no.2, 2017년, pp.154 - 160   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study

Machytka, Evzen (Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic ) ; Gaur, Shantanu (Allurion Technologies, Wellesley, Massachusetts, USA ) ; Chuttani, Ram (Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA ) ; Bojkova, Martina (Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic ) ; Kupka, Tomas (Internal Clinic, Department of Gastroenterology, University Hospital Ostrava, Ostrava, Czech Republic ) ; Buzga, Marek (Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic ) ; Giannakou, Andreas (Department of Surgery, Iatriko Medical Center, Palaio Faliro, Greece ) ; Ioannis, Kandiliotis (Department of Radiology, Iatriko Medical Center, Palaio Faliro, Greece ) ; Mathus-Vliegen, Elisabeth (Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands ) ; Levy, Samuel (Allurion Technologies, Wellesley, Massachusetts, USA ) ; Raftopoulos, Ioannis (Department of Surgery, Iatriko Medical Center, Palaio Faliro, Greece ) ;
  • 초록  

    Background and study aims Conventional gastric balloons for weight loss require endoscopy for placement and removal. The Elipse device is swallowed, resides in the stomach for 4 months, and is then expelled. The objectives of this study were to assess the safety of Elipse and to measure its effects on weight loss, metabolic parameters, and quality of life.Methods Each participant swallowed one Elipse device, which was filled with 550 mL of filling fluid through a thin delivery catheter that was then removed. Weight was measured every 2 weeks, and metabolic parameters and quality of life were assessed at baseline and at trial exit.Results 34 patients, with a mean body mass index of 34.8 kg/m2, were enrolled. All 34 patients successfully swallowed the Elipse device. All adverse events were either self-limiting or resolved with medication. All balloons were safely excreted. At 4 months, the mean percent total body weight loss was 10 %. Mean waist circumference was reduced by 8.4 cm. Improvements were also seen in hemoglobin A1c, triglycerides, low density lipoprotein, and blood pressure. At trial exit, quality of life measures had improved across all domains.Conclusion These results demonstrate clinically significant weight loss with the Elipse, the first procedureless gastric balloon. The weight loss was similar to that seen in previous studies of endoscopically placed balloons. In addition, Elipse therapy led to improvements in waist circumference, several metabolic parameters, and overall quality of life.ClinicalTrials.gov identifier: NCT 02802007.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기